Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

Autor: Van Der Zwan, Jan Maarten, Trama, Annalisa, Otter, Renã©e, Larraã±aga, Nerea, Tavilla, Andrea, Marcos-gragera, Rafael, Dei Tos, Angelo Paolo, Baudin, Eric, Poston, Graeme, Links, Thera, Zielonke, N., Van Eycken, E., Sundseth, H., Hedelin, G., Faivre, JULIEN YVES STEPHAN, Woronoff, A. S., Buemi, A., Tretarre, B., Colonna, Marco, Bara, S., Ganry, O., Grosclaude, P., Holleczek, B., Geissler, J., Tryggvadottir, L., Deady, S., Bellã¹, F., Ferretti, Silvia, Serraino, D., Vercelli, M., Vitarelli, S., Cirilli, C., Fusco, M., Traina, Angelo, Michiara, M., Giacomin, A., Tumino, R., Mangone, L., Falcini, F., Senatore, G., Budroni, M., Piffer, S., Crocetti, E., LA ROSA, FEDERICA IRENE, Contiero, P., Fiore, A., Gatta, G., Casali, P. G., Gronchi, A., Ruzza, Marta, Sowe, S., De Angelis, R., Dei Tos, A. P., England, K., Ursin, G., Rachtan, J., Gozdz, S., Zwierko, M., Slowinski, J., Miranda, A., Safaei Diba, C., Primic-zakelj, M., Mateos, A., Martã­nez, R., Torrella-ramos, A., Osca-gelis, G., Chirlaque, M. D., Moreno, C., Galceran, J., Martinez-garcia, C., Melchor, J. M., Sã¡nchez, M. J., Virizuela-echaburu, J. A., Cervantes, A., Adolfsson, J., Lambe, M., Mã¶ller, T. R., Ringborg, U., Jundt, G., Bouchardy, C., Ess, S. M., Bordoni, A., Konzelmann, I., Lutz, J. M., Visser, O., Siesling, S., Coebergh, J. W. W., Greenberg, D. C., Wilkinson, Robert John Duncan, Roche, M., Verne, J., Meechan, D., Lawrence, G., Coleman, M. P., Mackay, J., Gavin, A., Brewster, D. H., Kunkler, I., White, C.
Přispěvatelé: Damage and Repair in Cancer Development and Cancer Treatment (DARE), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Bouchardy Magnin, Christine
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Male
Pediatrics
Pathology
Cancer Research
MEDULLARY-THYROID CARCINOMA
Survival
Rare Diseases/epidemiology/mortality
Neuroendocrine Tumors/epidemiology/mortality
PROGNOSTIC-FACTORS
MERKEL CELL-CARCINOMA
Prevalence
EPIDEMIOLOGY
Cancer registry
Incidence
Prevalence
Survival
Neuroendocrine
Registries
Child
education.field_of_study
Relative survival
Merkel cell carcinoma
Incidence (epidemiology)
Incidence
Middle Aged
Cancer registry
Europe
Neuroendocrine Tumors
Neuroendocrine
Oncology
Child
Preschool
Epidemiological Monitoring
Female
Adult
medicine.medical_specialty
Adolescent
Population
UNITED-STATES
DIAGNOSIS
Europe/epidemiology
NO
PERIOD ANALYSIS
Young Adult
Rare Diseases
Carcinoma
medicine
Rare neuroendocrine tumours
Humans
education
Survival analysis
ddc:613
Aged
business.industry
Infant
Newborn
Cancer
Infant
NATURAL-HISTORY
medicine.disease
Survival Analysis
STAGING-SYSTEMS
business
Zdroj: European Journal of Cancer, 49(11), 2565-2578. ELSEVIER SCI LTD
European Journal of Cancer, Vol. 49, No 11 (2013) pp. 2565-2578
ISSN: 0959-8049
Popis: Because of the low incidence, and limited opportunities for large patient volume experiences, there are very few relevant studies of neuroendocrine tumours (NETs).A large population-based database (including cancer patients diagnosed from 1978 to 2002 and registered in 76 population-based cancer registries [CRs]), provided by the project 'surveillance of rare cancers in Europe' (RARECARE) is used to describe the basic indicators of incidence, prevalence and survival of NETs, giving a unique overview on the burden of NETs in Europe. NETs at all cancer sites, excluding lung, were analysed in this study. In total over 20,000 incident cases of NETs were analysed and a data quality check upon specific NETs was performed. The overall incidence rate for NETs was 25/1,000,000 and was highest in patients aged 65 years and older with well differentiated endocrine carcinomas (non-functioning pancreatic and gastrointestinal) (40 per 1,000,000). We estimated that slightly more than 100,000 people were diagnosed with NETs and still alive in EU27 at the beginning of 2008. Overall, NETs had a 5 year relative survival of 50%; survival was low (12%) for poorly differentiated endocrine carcinoma, and relatively high (64%) for well differentiated carcinoma (not functioning of the pancreas and digestive organs). Within NETs, endocrine carcinoma of thyroid gland had the best 5-year relative survival (82%).Because of the complexity and number of the different disciplines involved with NETs (as they arise in many organs), a multidisciplinary approach delivered in highly qualified reference centres and an international network between those centres is recommended. (c) 2013 Elsevier Ltd. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: